Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
AstraZeneca (AZN) Q4 Earnings Beat, Sales Hurt by COVID Jab
01:39pm, Thursday, 09'th Feb 2023 Zacks Investment Research
AstraZeneca (AZN) beats fourth-quarter estimates for earnings while missing the same for sales.
Big Pharma's Big Gains
02:14am, Thursday, 09'th Feb 2023
Given enough time, stock in pharmaceutical giants has yielded life-altering gains. Because of its popular and widely distributed COVID-19 vaccine, Pfizer has sparked more controversy than other stocks
Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023
07:27pm, Wednesday, 08'th Feb 2023 Benzinga
Mizuho raised the price target on BioXcel Therapeutics Inc (NASDAQ: BTAI) from $24 to $38, with a Buy rating.
Since the analyst's previous model update last December, BTAI shares have meaningfully
A Look at Pharma ETFs Post Q4 Earnings
03:05pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.
2 Top Biotech Stocks to Buy in February
02:45pm, Wednesday, 08'th Feb 2023 The Motley Fool
Biotech stocks aren't all created equal -- these two are the best of the bunch.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
11:20am, Wednesday, 08'th Feb 2023 Zacks Investment Research
Smart Beta ETF report for PJP
AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?
03:26pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
02:00pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Merck Stock a Buy After Post-Earnings Sell-Off?
12:32pm, Tuesday, 07'th Feb 2023 Investing.comMerck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
10:33am, Tuesday, 07'th Feb 2023
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
07:00am, Tuesday, 07'th Feb 2023
During this earnings season good news hasn't been enough for some investors. That was the case with Merck & Co., Inc. (NYSE: MRK).
These 5 timely stocks from a top international fund manager can help your portfolio take on the world
09:34pm, Monday, 06'th Feb 2023 MarketWatch
Nicole Kornitzer discusses her strategy for the Buffalo International Fund
Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down
06:41pm, Monday, 06'th Feb 2023 Benzinga
Needham has upgraded Personalis Inc (NASDAQ: PSNL) to Buy from Hold with a price target of $8.
The analyst writes that Personalis's cash burn has likely peaked and expects it to decline steadily o
The 7 Most Undervalued Blue-Chip Stocks to Buy in February 2023
09:45am, Sunday, 05'th Feb 2023
Blue-chip stocks are recognized as being among the largest, most stable stocks an investor can own. And in this article, we'll be looking at seven undervalued blue-chip stocks to consider now.
5 Relatively Safe And Cheap Dividend Stocks To Invest In - February 2023
02:00pm, Saturday, 04'th Feb 2023 Seeking Alpha
This is part of our monthly series where we highlight 5 companies that are large-cap, relatively safe, dividend-paying, and offer discounts. Click here for more.
